Evidence map›Paper›PMID 37641937›Full record

ReviewThe British journal of nutrition2024

Grant M Tinsley, Andrew R Jagim, Gregory D M Potter, Dan Garner, Andrew J Galpin

Open access · hybridAbstract readReview
In one paragraph

Review in The British journal of nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. The effect ofFrontiers in nutrition · 2025
    Pooled it
  3. Effects of Maca (Nutrients · 2024
    Pooled it
  4. Effects of Caffeine andNutrients · 2026
    Trial
  5. Trial
  6. Effects ofNutrients · 2026
    Trial
  7. Trial
  8. Trial
  9. The Effect of Short-TermNutrients · 2025
    Trial
  10. Trial
  11. Trial
  12. Herbacetin as a novel therapeutic agent for pulmonary and renal fibrosis by targeting TGFBR2 for degradation.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Development of Orally Disintegrating Tablets of StandardizedPharmaceuticals (Basel, Switzerland) · 2025
    Article
  20. The Effect of Rosavin, a Characteristic Compound ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Grant M TinsleyDepartment of Kinesiology and Sport Management, Texas Tech University, Lubbock, TX79409, USA.ORCID 0000-0002-0230-6586
Andrew R JagimSports Medicine, Mayo Clinic Health System, La Crosse, WI, USA.
Gregory D M PotterGreg Potter PhD Limited, Brighton, East Sussex, UK.
Dan GarnerBioMolecular Athlete, LLC, Wilmington, DE, USA.
Andrew J GalpinBioMolecular Athlete, LLC, Wilmington, DE, USA.
California State University, Fullerton · USEast Sussex County Council · GBMayo Clinic Health System · USTexas Tech University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Performance-Enhancing SubstancesRhodiolaAdultAntioxidantsExerciseFemaleHumansMalePlant ExtractsAntioxidantsPerformance-Enhancing SubstancesPlant ExtractsArctic rootDietary supplementGolden rootPhysical performanceRosavinRoserootSalidroside

Identifiers

PMID37641937
PMCPMC10784128
OpenAlexW4386251880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.